
ERRATUM

In the article by Blazar et al, entitled “Rapamycin, a Potent Inhibitor of T-Cell Function, Prevents Graft Rejection in Murine Recipients of Allogeneic T-Cell–Depleted Donor Marrow,” which appeared in the January 15, 1994 issue (Vol 83, No 2, pp 600-609), Table 6 on page 605 was incorrect. The corrected version is printed on the next page.

Table 6. Long-Term Peripheral Blood Reconstitution in Irradiated Recipients of Isolated MHC Class I or Class II Only Disparate TCD Donor Bone Marrow

Donor	Recipient	In Vivo Host Treatment	Donor T Cells			Host T Cells			Donor			Host		
			CD4 ⁺	CD8 ⁺	CD8 ⁺	CD4 ⁺	CD8 ⁺	CD8 ⁺	B Cells	Granulocytes	B Cells	Granulocytes	B Cells	Granulocytes
B6.C-H-2 ^{bm1}	C57BL/6-Ly5.2	PBS	0 ± 0	0 ± 0	0 ± 0	29 ± 2	14 ± 1	0 ± 0	0 ± 0	0 ± 0	25 ± 3	25 ± 1		
B6.C-H-2 ^{bm1}	C57BL/6-Ly5.2	RAPA 1.5 mg/kg/dose	10 ± 1*	6 ± 1*	3 ± 0*	3 ± 0*	2 ± 0*	42 ± 4*	13 ± 4*	7 ± 1*	5 ± 1*			
B6.C-H-2 ^{bm1}	C57BL/6-Ly5.2	Anti-CD4 MoAb	0 ± 0	0 ± 0†	15 ± 1††	10 ± 2†	0 ± 0†	0 ± 0†	0 ± 0†	18 ± 1††	42 ± 2*†			
B6.C-H-2 ^{bm1}	C57BL/6-Ly5.2	Anti-CD8 MoAb	12 ± 1*	0 ± 0†	8 ± 1††	0 ± 0††	0 ± 0††	51 ± 2*	8 ± 2*	5 ± 1*	3 ± 1*			
B6.C-H-2 ^{bm12}	C57BL/6-Ly5.2	PBS	4 ± 1	2 ± 0	27 ± 2	14 ± 1	1 ± 1	1 ± 1	1 ± 0	25 ± 3	19 ± 1			
B6.C-H-2 ^{bm12}	C57BL/6-Ly5.2	RAPA 1.5 mg/kg/dose	10 ± 1*	4 ± 1	3 ± 0*	3 ± 0*	3 ± 0*	44 ± 2*	10 ± 2*	8 ± 1*	5 ± 0*			
B6.C-H-2 ^{bm12}	C57BL/6-Ly5.2	Anti-CD4 MoAb	6 ± 1†	3 ± 0	6 ± 2*	7 ± 1††	7 ± 1††	12 ± 5††	22 ± 6*	9 ± 3*	13 ± 2†			
B6.C-H-2 ^{bm12}	C57BL/6-Ly5.2	Anti-CD8 MoAb	5 ± 2†	0 ± 0†	31 ± 2†	2 ± 1*	2 ± 1*	1 ± 0†	1 ± 0†	29 ± 3†	20 ± 2†			

To study the effect of rapamycin (RAPA) treatment on class I bone marrow rejection. T-cell-depleted bone marrow from B6.C-H-2^{bm1} mice (with a class I point mutation) was administered to irradiated C57BL/6-Ly5.2 congenic mice to induce CD8⁺ T-cell mediated MHC class I restricted rejection. B6.C-H-2^{bm12} cells (with a class II point mutation) were given to induce CD4⁺ T-cell mediated MHC class II restricted graft rejection. Peripheral blood cells obtained 59 days post-bone marrow transplantation were analyzed by three-color flow cytometry for donor origin, host origin, and T cell (CD4 or CD8), B-cell (B220⁺), or granulocyte (gran-1⁺) lineages. Values are mean percentages ± 1 standard error of the mean for the percentages of each cell population listed.

Abbreviations: MoAb, monoclonal antibody; PBS, phosphate-buffered saline.

* P < .05 compared with PBS control.

† P < .05 compared with the RAPA-treated group.